Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib-Reference-Cited by-同舟云学术

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib

Published:2010-09 Issue:6 Volume:103 Page:796-801
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Flaig T W,Costa L J,Gustafson D L,Breaker K,Schultz M K,Crighton F,Kim F J,Drabkin H

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605868.pdf

Reference22 articles.

1. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25: 4536–4541

2. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750–758

3. Costa LJ, Gemmill RM, Drabkin HA (2007) Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 69: 596–602

4. Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A (2004) A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10: 7812–7819

5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SMEK1 promotes clear cell renal cell carcinoma progression via EGFR tyrosine-kinase dependent pathway;Cancer Letters;2024-10

2. Erlotinib;Adverse Events and Oncotargeted Kinase Inhibitors;2017

3. Erlotinib;Meyler's Side Effects of Drugs;2016

4. Sirolimus;Meyler's Side Effects of Drugs;2016

5. Induction of Epithelial-Mesenchymal Transition via Activation of Epidermal Growth Factor Receptor Contributes to Sunitinib Resistance in Human Renal Cell Carcinoma Cell Lines;Journal of Pharmacology and Experimental Therapeutics;2015-08-25